We have recently shown that interleukin-9 (IL-9) strongly stimulates the proliferation of mouse thymic lymphomas in vitro. Here we report that this factor is also one of the most potent inhibitors of apoptosis induced by dexamethasone (DEX) in such cell lines, even if they do not depend on exogenous factors for growth. For the murine thymic lymphoma BW5147, protection against apoptosis was also obtained with IL-4 and less strongly with IL-6, whereas IL-2, IL-7, and IL-10 were inactive. Moreover, IL-4 and IL-9 maintained proliferation of these cells in the presence of DEX. Analysis of eight other factor-independent thymic lymphoma lines is a T-cell-derived cytokine with pleiotropic activities on various cell types.' Although it was initially described as a T-cell growth factor for mouse T-helper cell clones,' the role of this cytokine in T-cell development and function remains elusive. With the exception of day 15 fetal thymocytes, where a strong synergy is observed between IL-2 and IL-9, freshly isolated normal T cells do not proliferate in response to this cytokine.'.' By contrast, IL-9 has been shown to be a potent inducer of proliferation for mouse thymic lymphomas in vitro.' Moreover, dysregulated expression of the IL-9 gene in transgenic mice results in the sporadic development of spontaneous thymic lymphomas and in a dramatic increase in susceptibility to the induction of such tumors by mutagens or x-ray irradiation." In the human, recent observations have shown that IL-9 responsiveness is highly restricted by the stage of activation of T-cell lines,' and a putative involvement in tumorigenesis has been suggested by the demonstration of an autocrine loop in a Hodgkin's lymphoma cell line in vitro.x Apoptosis plays an essential role in thymic development, as immature cells are constantly eliminated by this process as a result of antigen-receptor stimulation""' and exposure to glucocorticoids." Although their physiologic role in thymic ontogeny is not completely clear, cytokines have been shown to interfere with this process in vitro. IL-1 has been shown to inhibit CD3-induced T-cell death, while IL-4 was found to protect double-negative and CD4 single-positive thymocytes against the glucocorticoid analogue dexamethasone (DEX ence intrathymic T-cell development, not only by stimulating cell proliferation but also by controlling apoptosis. Thymic lymphomas retain many characteristics of normal thymocytes. They proliferate in response to T-cell growth factors such as 1L-2. 1L-4, and IL-75 and frequently undergo apoptosis in the presence ofDEX.I4 Cell lines that proliferate autonomously but retain sensitivity to DEX-induced apoptosis can be derived from such tumors, thus providing a unique opportunity to investigate cytokine anti-apoptotic properties without interference by stimulation of cell growth. By protecting thymic lymphoma cells against apoptotic death, cytokines could play an important role in the development of T-cell tumors that do not require any cytokine for proliferation but are sensitive to inducers of apoptosis. Here we report that IL-9 and IL-4 are potent inhibitors of glucocorticoid-induced apoptosis and cell growth arrest in factorindependent thymic lymphoma cell lines. By contrast, IL-2 seems to be more efficient in triggering proliferation than in protecting against apoptosis. suggesting that distinct mechanisms are involved in these processes.
NTERLEUKIN-9 (IL-9)
is a T-cell-derived cytokine with pleiotropic activities on various cell types.' Although it was initially described as a T-cell growth factor for mouse T-helper cell clones,' the role of this cytokine in T-cell development and function remains elusive. With the exception of day 15 fetal thymocytes, where a strong synergy is observed between IL-2 and IL-9, freshly isolated normal T cells do not proliferate in response to this cytokine.'.' By contrast, IL-9 has been shown to be a potent inducer of proliferation for mouse thymic lymphomas in vitro.' Moreover, dysregulated expression of the IL-9 gene in transgenic mice results in the sporadic development of spontaneous thymic lymphomas and in a dramatic increase in susceptibility to the induction of such tumors by mutagens or x-ray irradiation." In the human, recent observations have shown that IL-9 responsiveness is highly restricted by the stage of activation of T-cell lines,' and a putative involvement in tumorigenesis has been suggested by the demonstration of an autocrine loop in a Hodgkin's lymphoma cell line in vitro. x Apoptosis plays an essential role in thymic development, as immature cells are constantly eliminated by this process as a result of antigen-receptor stimulation""' and exposure to glucocorticoids." Although their physiologic role in thymic ontogeny is not completely clear, cytokines have been shown to interfere with this process in vitro. IL-1 has been shown to inhibit CD3-induced T-cell death, while IL-4 was found to protect double-negative and CD4 single-positive thymocytes against the glucocorticoid analogue dexamethasone (DEX)."." These results suggest that cytokines may influ- ence intrathymic T-cell development, not only by stimulating cell proliferation but also by controlling apoptosis. Thymic lymphomas retain many characteristics of normal thymocytes. They proliferate in response to T-cell growth factors such as 1L-2. 1L-4, and IL-75 and frequently undergo apoptosis in the presence ofDEX.I4 Cell lines that proliferate autonomously but retain sensitivity to DEX-induced apoptosis can be derived from such tumors, thus providing a unique opportunity to investigate cytokine anti-apoptotic properties without interference by stimulation of cell growth. By protecting thymic lymphoma cells against apoptotic death, cytokines could play an important role in the development of T-cell tumors that do not require any cytokine for proliferation but are sensitive to inducers of apoptosis. Here we report that IL-9 and IL-4 are potent inhibitors of glucocorticoid-induced apoptosis and cell growth arrest in factorindependent thymic lymphoma cell lines. By contrast, IL-2 seems to be more efficient in triggering proliferation than in protecting against apoptosis. suggesting that distinct mechanisms are involved in these processes. Plymouth Meeting, PA) and cyclosporin A (CsA) were used at 5 nglmL and 1 pglmL, respectively.
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MATERIALS AND METHODS
Assessment of DNA frapnenmtion. BW5147 cells were incubated for 2 days in normal culture medium or in the presence of IL-9 (0.5 X IO-' mol/L) before addition of DEX (0.25 X IO-" mol/L). Cells were centrifuged 24 hours later; resuspended in lysis buffer containing 0.15 mol/L NaCI, 10 mmol/L Tris pH 8, 12.5 mmol/L EDTA, 0.5% sodium dodecyl sulfate (SDS), and 0.5 mglmL proteinase K; and incubated overnight at 56°C. After extraction with phenol and chloroform, the DNA was precipitated with isopropyl alcohol, resuspended in TE buffer (10 mmol/L Tris pH 8, 1 mmol/L EDTA) and incubated at 37°C with 0.5 mglmL RNAse for I hour before electrophoresis in a 2% agarose gel.
Viability and proliferation assq.v. Cell viability was determined using a propidium iodide incorporation assay as described." Briefly, cells were incubated for 30 minutes with propidium iodide (125 pgl mL) at room temperature before fluorescence-activated cell sorting (FACS) analysis with an ATC3000 flow cytometer (Odam, Wissembourg, France). Under these conditions, dead cells are brightly stained, while live cells are not. A minimum of 5,OOO cells were counted per sample.
To test the influence of cytokines on proliferation in the presence of DEX. thymic lymphoma cell lines were incubated overnight in triplicate microtiter wells with or without cytokines before addition of DEX to a final 0.25 X IO-' mollL concentration in a 200-pL volume. Unless stated otherwise, the cytokine concentrations used were as follows: IL-la, 20 UlmL: IL-2. 50 UlmL; IL-4. 250 UlmL; IL-6. 1,000 UlmL: IL-7. 10 ng/mL; IL-9, 500 UlmL: IL-IO. 10 ngl mL; IL-13, 1 0 0 nglmL; IFNy, 1 0 0 UlmL; and TNFa, 1 0 0 UlmL. These concentrations were at least 10-fold higher than doses giving a maximal activity of the factors in their respective bioassays. Cultures were pulsed 2 to 4 days later for 6 hours with 0.5 pCi 'Hthymidine. Alternatively, cell proliferation was measured by an hexosaminidase assay, as described.'
RESULTS
IL-9 inhibits DEX-induced apoptosis in B W5147
thynic /vn7phorna cell line. IL-9 is a potent stimulator of thymic tumor cell proliferation, but its ability to inhibit apoptosis has not yet been investigated. To evaluate possible antiapoptotic activity mediated by IL-9, we selected BWS147, a thymic lymphoma that proliferates actively in vitro without cytokines and undergoes apoptotic cell death in the presence of DEX. Cells incubated with or without a saturating dose of IL-9 were exposed to DEX for 30 hours. Genomic DNA was extracted and analyzed by gel electrophoresis to detect fragmentation into 200-bp fragments as a reflection of apoptosis. Cell viability was also measured by FACS after staining with propidium iodide. As indicated in Fig I , exposure to DEX induced a strong DNA fragmentation and approximately 30% cell death after 30 hours. Both processes were almost completely inhibited by IL-9 (Fig l) . Pretreatment of BW5147 with IL-9 was, in fact, not necessary, as cells were protected as efficiently when the cytokine was added at the same time as DEX (data not shown).
Activity of other cytokines in protecting BW5147 against DEX-induced apoptosis. To evaluate the antiapoptotic activity of other cytokines, BW5147 cells were incubated with a series of different factors before addition of DEX. Cell mortality was measured by propidium iodide staining after For a 24-hour exposure to DEX. This analysis showed that, IL-4 and IL-6, in addition to IL-9, also inhibited DEX-induced mortality, whereas IL-l, IL-2, IL-7, and IL-IO were inactive. By contrast, TNF-a and, to a lesser extent, IFN-y increased DEX-induced mortality (Fig 2) . Interestingly, IL-9 also inhibited the increment in mortality induced by these factors (data not shown).
As inhibition of DEX-induced apoptosis does not necessarily result in cell proliferation, we evaluated the growthstimulatory activity of cytokines on BWS147 cells in the presence of DEX. With DEX alone, the Proliferation was inhibited by 90% to 95% (data not shown). By contrast, in the presence of IL-9, a strong proliferation was observed in thymidine incorporation or hexosaminidase assays. Lower but significant levels of protection were obtained with IL-4 and IL-6, whereas other cytokines, such as IL-la, 1L-2, IL-10, and IL-13, were inactive (Fig 3) . Concentrations of IL-4 required to maintain proliferation were much higher than those of IL-9. Half-maximal protection required SO0 pmol/ L for IL-4, while the same result was obtained with 5 pmol/ L IL-9, this sensitivity making BW5147 in the presence of DEX equivalent to the most sensitive biologic assay for IL-RENAULD ET AL 9 described so far.2 For IL-6, the half-maximal effect was obtained at a concentration on the order of 10 pmol/L, which is similar to that which induces half-maximal responses in fresh mouse T cells" (Fig 4) .
To test whether the protective activities of IL-4 and 1L-9 against DEX were long-lasting, cell cultures were established with or without DEX and successively diluted for 2 weeks. As shown in Fig S, the protective activities of either factor allowed for permanent growth in the presence of DEX. Over a 12-day period, the number of divisions was 39 in the absence of DEX and 29 or 26 with DEX and XL-9 or IL-4, respectively. With DEX in the absence of cytokines, viable cells could no longer be detected after 1 week. Without DEX, cytokines do not affect cell growth (data not shown).
Eject .f staurosporin and CsA on rescue meclzunisms triggered by cytokines in DEX-treuted BW5147 cells.
To begin to analyze the signal transduction mechanisms involved in the anti-apoptotic activity of IL-9, IL-4, and IL-6, we evaluated the effect of staurosporin (an inhibitor for a large variety of kinases) and CsA. Although these reagents did not affect cell viability in normal medium, they significantly accelerated DEX-induced cell death. In the presence of S ng/mL of staurosporin, the activities of IL-4 and 1L-9 were completely blocked, while IL-6 had still a weak but reproducible activity. By contrast, CsA at l pg/mL did not affect the protection conferred by IL-4 or IL-9 but significantly reduced the effect of IL-6 (Fig 6) . These results suggest that distinct signaling pathways are activated by IL-9 and IL-4 on the one hand and IL-6 on the other. or without cytokines for 24 or 48 hours before addition of DEX. Significant inhibition (at least 20%) of DEX-induced cell death was observed in seven cell lines with IL-9, in six with IL-4, in three with 1L-7. and in two with IL-2 (Fig 7) . However, reversal of the antiproliferative activity of DEX by cytokines was not observed in all thymic lymphoma cell lines where significant inhibition of apoptosis had been detected: in three of the seven cell lines tested, we did not detect significant growth in the presence of DEX with IL-2, 1L-4, IL-7, or IL-9 ( Table l ) . The failure of cytokines to maintain proliferation in the presence of DEX in these cells contrasted with their strong anti-apoptotic activities observed with the same cells, indicating that protection against apoptosis does not automatically correlate with cell proliferation.
Activity of T-cell growth ,factors against DEX-induced upoptosis
To compare the efficiency of IL-9 and IL-2 to induce proliferation and to protect against apoptosis, we used the lymphoma cell line 9T7, which proliferates autonomously but whose growth can still be stimulated by IL-2. In the absence of DEX, IL-9 stimulates 9T7 proliferation only poorly, whereas IL-2 induces a 100% increase in thymidine incorporation. By contrast, in the presence of DEX, IL-9 was found to be more efficient than IL-2 to protect cells against apoptosis (35% U 17% of cytokine-induced protection). Moreover, when IL-9 and IL-2 were combined, additive effects were observed both for proliferation and protection against apoptosis (Fig 8) , further suggesting that the mechanisms involved in the activities of these cytokines are distinct.
DISCUSSION
The results presented here show that IL-9 is a potent inhibitor of glucocorticoid-induced apoptosis in thymic lymphoma cell lines that do not depend on cytokines for growth. For the BW5147 lymphoma cell line, IL-4 was an equally potent inhibitor of apoptosis as 1L-9, but with a lower specific activity. IL-6 also reduced DEX-induced cell death, but less than the two other factors. Attempts to prevent the anti-apoptotic activity of IL-9, IL-4, and IL-6 with staurosporin or CsA showed a definite difference: whereas the anti-apoptotic activity of IL-4 and IL-9 was inhibited by staurosporin and not by CsA, the converse was true for IL-6. The opposite effects of these two reagents suggest that the anti-apoptotic activity of IL-6 involves different mechanisms than those triggered by IL-4 and IL-9. Comparison of the anti-apoptotic properties of various cytokines on different cell lines indicates that IL-4 and IL-9 give the best protection against DEX. Protection was also observed, but less frequently, with IL-7, while IL-2 was poorly active in this kind of assay.
The strong inhibition by IL-9 of DEX-induced apoptosis in thymic lymphoma cell lines contrasts with the absence of proliferative activity observed with freshly isolated thymocytes and further shows the preferential action of IL-9 on activated or transformed T cells. Recent observations have indeed shown that resting human T cells are clearly unresponsive to IL-9 but become responsive soon after in vitro preactivation.' The fact that thymic progenitors similarly acquire IL-9 responsiveness upon transformation was previously reported for freshly isolated tumoral samples.' Moreover, we found recently that constitutive IL-9 expression in vivo does not affect the normal thymic development but results in an abnormally high incidence of thymic lymphomas.' The present demonstration that IL-9 is particularly efficient in the inhibition of apoptosis. in addition to its ability to stimulate cell growth. provides a potential explanation for these results, as apoptosis is a characteristic of proliferating cells. Contrary to IL-9, IL-2 exhibits a poor anti-apoptotic activity on the thymic lymphoma cell lines used in this study. A simple explanation for this observation would be the loss of IL-2 receptor-a expression by some tumors. Nevertheless. < l 0 0 <l00 <l00 <l00 <l00 <l00 < l 0 0 <l00 <l00 <l00 <l00
Cells (3,000 BR13, 9T4A2, and TH1821 cells; 5,000 9T7.9C1 cells; 7,000 NMZTl cells: and 30,000 NM3T2 and BR14T2 cells) were incubated in microwells in the presence or absence of DEX and the indicated cytokines for 2 to 3 days before measuring 3H-thymidine incorporation. Results are expressed in cpm and correspond to the mean of triplicate cultures. Standard deviations were less than 10%.
the levels of protection against DEX provided by IL-2 on cells that express functional IL-2 receptors are rather week as compared with those conferred by IL-4 or IL-9. Moreover, when we used the 9T7 lymphoma cell line, where IL-2 receptor-a was expressed and whose spontaneous proliferation rate could still be enhanced by IL-2, only minimal protection against DEX was obtained with this factor. IL-9, on the contrary. had a negligible stimulatory effect on cell growth but inhibited apoptosis more clearly. The fact that IL-9 strongly protected several cell lines against apoptosis while failing to maintain cell proliferation further suggests that distinct regulatory elements are involved in these two processes.
Interestingly, with 9T7 cells, combination of IL-2 and For personal use only. on July 15, 2017. by guest www.bloodjournal.org From IL-9 showed an additive activity both for proliferation and protection against apoptosis. In another cell line, proliferation in the presence of DEX required the combination of IL-2 and IL-9 (data not shown), further demonstrating the synergistic interaction between IL-2 and E -9 originally observed for the proliferation of fetal thymocyte^.^ In light of these results, an attractive explanation for this synergy might be that IL-2 and IL-9 act preferentially on two distinct and complementary aspects of cell growth: cell division for IL-2 and cell survival for IL-9.
The present study indicates that the putative role of cytokines, and particularly of IL-9, in the development of thymic lymphomas is not limited to cells that depend on these factors for proliferation. This possibility enlarges the spectrum of activities of these molecules with respect to tumors that are sensitive to inducers of apoptosis in vivo. The importance of this function has been clearly demonstrated by the finding that IFN-y, which is constitutively produced in B-cell chronic lymphocytic leukemia, protects these cells against apoptosis without stimulating their proliferation." Further studies will have to assess the hypothesis of a similar role for IL-9 in lymphoid malignancies in which an IL-9 autocrine loop has been suggested.8
